Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025
DOI: 10.1016/j.bbcan.2025.189496 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Xiangyu Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, …. Hauptthemen laut MEDLINE: Galectins, B7-H1 Antigen, Neoplasms, Programmed Cell Death 1 Receptor. Die Arbeit nennt 79 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Natural Science Foundation.
Abstract (Originalsprache)
Despite advances in PD-1/PD-L1 combination therapies, clinical benefits remain limited and toxicity is significant. Galectins, a family of β-galactoside-binding lectins, have emerged as mechanistically distinct, multimodal targets with the potential to address these limitations. By modulating glycan-protein networks in the tumor microenvironment, galectin inhibition alleviates T cell exclusion, immune exhaustion, immunosuppressive cell activation, and steric blockade of PD-(L)1 antibodies. Several galectin inhibitors (e.g., GR-MD-02, GB1211, LYT-200) are under clinical evaluation. Early trials showing encouraging efficacy-toxicity profiles and some combinations received FDA Fast Track designations. This review summarizes mechanistic and clinical advances and highlights their translational implications for galectin-targeted combination therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Xuhui District, Shanghai 200032, China.
- NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 130 Dong'an Road, Xuhui District, Shanghai 200032, China. Electronic a…
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Natural Science Foundation
Zitieren
APA
Huang, X., Zhang, S., Li, J., & Chen, S. (2025). Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189496
Vancouver
Huang X, Zhang S, Li J, Chen S. Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189496
BibTeX
@article{Huang2025,
author = {Huang, Xiangyu and Zhang, Si and Li, Jiale and Chen, She},
title = {Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
doi = {10.1016/j.bbcan.2025.189496}
}
EUVIMED